background

Pipeline

We are dedicated to reimagining how cancer is treated and focused on developing potential first- and best-in-class solutions that support patient journeys. With a determination to realize a future in which people with cancer live longer and better than ever before, Syndax is unwaveringly committed to delivering new treatment options for cancer patients that provide meaningful and differentiated results. 

We have a proven ability to advance innovative and differentiated cancer programs and a strong record of adhering to scientific excellence, following promising clinical data and real-world utilization.

Revumenib and axatilimab have the potential to be approved in the U.S. in 2024, with several opportunities for franchise expansion.

RevumenibRevumenibRead more

Menin-KMT2A Disruption

Phase 1

Phase 2

Pivotal

Registration

Indication(s)

Stage

  • AUGMENT-101-2A

    monotherapy

    Read more
    R/R KMT2Ar ALL
    registration
  • AUGMENT-101-2B

    monotherapy

    Read more
    R/R KMT2Am AML
    registration
  • AUGMENT-101-2C

    monotherapy

    Read more
    R/R NPM1m AML
    pivotal
  • AUGMENT-102

    chemotherapy combination

    Read more
    R/R KMT2Ar and NPM1m acute leukemias
    phase-1
  • BEAT-AML

    ven/aza combination

    Frontline KMT2Ar and NPM1m AML
    phase-1
  • INTERCEPT

    monotherapy

    MRD- progression in KMT2Ar and NPM1m AML
    phase-1
  • Colorectal Cancer

    monotherapy

    Unresectable metastatic microsatellite stable CRC
    phase-1

AxatilimabAxatilimabRead more

Anti-CSF-1R mAb

Phase 1

Phase 2

Pivotal

Registration

Indication(s)

Stage

  • AGAVE-201

    monotherapy

    Read more
    Chronic GVHD
    registration
  • Idiopathic Pulmonary Fibrosis

    monotherapy

    Idiopathic Pulmonary Fibrosis
    phase-2

EntinostatEntinostatRead more

Class 1 HDAC Inhibitor

Under regulatory review in China

  • Entinostat

    Under review
    preclin